Cognito Trial Misses Primary Endpoint for Alzheimer's Device
Cognito Therapeutics presented Phase 3 HOPE study results for its at-home Spectris AD therapy at the CTAD conference.
Updated on Nov. 17, 2026 in Alzheimer’s

Live Poll
Would you trust an at-home Alzheimer's device even if its main trial missed?
Cognito Therapeutics presented results from the Phase 3 HOPE study of Spectris AD, an investigational non-invasive at-home Alzheimer's therapy, at the Clinical Trials on Alzheimer's Disease conference. The study did not meet its primary endpoint.
Why it matters
The trial's failure on its primary measure leaves the device's effectiveness unproven at the level regulators typically require. A prespecified analysis favoring Spectris among participants with mild Alzheimer's suggests a possible signal that would need further study.
The evidence is a Phase 3 HOPE trial result presented at CTAD, with the primary endpoint missed and a prespecified subgroup analysis of mild Alzheimer's participants favoring Spectris on cognition and daily function. The full effect sizes and participant counts were not included in the available extraction, and whether the subgroup finding will hold in a confirmatory trial remains unknown.
The players
Cognito Therapeutics
Cognito Therapeutics is a company developing non-invasive brain stimulation technology, including the Spectris AD platform for Alzheimer's disease.
The details
Spectris AD uses light and sound stimulation to engage gamma-frequency brain activity and is used at home without invasive procedures. The company presented the HOPE study results at the Clinical Trials on Alzheimer's Disease conference, where the overall primary endpoint was not met.
Timeline
November 16, 2026: Cognito presented Phase 3 HOPE results at the CTAD conference.
Health Landscape
The results were shared at the Clinical Trials on Alzheimer's Disease conference, a central venue for Alzheimer's trial data. The source notes that future approaches could combine therapeutics and devices to address the disease from multiple angles.
Spectris AD is an investigational therapy and is not yet an available treatment option for patients. The trial's missed primary endpoint means the device's benefit has not been established for the broader patient population.
The takeaway
Investigational devices can show promising subgroup signals while still failing their main trial goal, so the results need confirmation before they guide care. Patients considering new Alzheimer's treatments should discuss evolving evidence with their clinicians.
Further reading
Explore more on Alzheimer’s research and treatment developments.
Source note: This article includes information reported by The Herald-Dispatch.
Live Poll
Would you trust an at-home Alzheimer's device even if its main trial missed?










